About: Antimicrobial resistant and extended-spectrum ß-lactamase (ESBL) producing Escherichia coli isolated from fecal samples of African dromedary camels

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antimicrobial resistant and extended-spectrum ß-lactamase (ESBL) producing Escherichia coli isolated from fecal samples of African dromedary camels Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Antimicrobial resistant and extended-spectrum ß-lactamase (ESBL) producing Escherichia coli isolated from fecal samples of African dromedary camels
Creator	Liljander, Anne Baschera, Melinda Jores, Jörg Nüesch-Inderbinen, Magdalena Stephan, Roger Kindle, Patrick Corman, Victor
source	Elsevier; PMC
abstract	Abstract This study was conducted to determine the distribution of antimicrobial resistance among Escherichia coli isolated from feces of healthy dromedary camels in Kenya. A total of 162 fecal samples were cultivated for E. coli. Samples were also subcultivated to detect E. coli with extended-spectrum ß-lactamases (ESBLs). Antimicrobial susceptibility testing (AST) was performed by disk diffusion using a panel of 16 antimicrobials. In addition, isolates were screened for the presence of the plasmid-mediated colistin resistance genes mcr-1 to mcr-5. Samples from 20 (12.4%) of the camels contained antimicrobial resistant (AMR) E. coli, and 85% of the AMR isolates were multidrug resistant (MDR). The highest frequency of resistance was observed to tetracycline (11.7%), followed by ampicillin and streptomycin (both 10.5%), and sulfamethoxazole/trimethoprim (9.9%). Two (1.2%) of the isolates showed intermediate resistance to cefazolin and streptomycin, respectively. All the isolates were susceptible to amoxycillin/clavulanic acid, ciprofloxacin, fosfomycin, aztreonam and kanamycin, and 86.4% of the isolates were susceptible to all 16 antimicrobials used in this study. The prevalence of fecal carriage of ESBL producing E. coli was 0.6%. PCR and amplicon sequencing showed that the ESBL producer belonged to E. coli phylogenetic group A, sequence type (ST) 48, and harbored bla CTX-M-15. None of the isolates contained mcr genes. The results indicate that dromedary camels in Kenya may be reservoirs of AMR E. coli, including ESBL producers, that could potentially be transmitted to humans by direct contact or via the food chain.
has issue date	2020-03-31(xsd:dateTime)
bibo:doi	10.1016/j.sciaf.2020.e00274
has license	els-covid
sha1sum (hex)	93d4534eecee1fe4ccfb36ea1449d53323127a9c
schema:url	https://doi.org/10.1016/j.sciaf.2020.e00274
resource representing a document's title	Antimicrobial resistant and extended-spectrum ß-lactamase (ESBL) producing Escherichia coli isolated from fecal samples of African dromedary camels
has PubMed Central identifier	PMC7148658
schema:publication	Scientific African
resource representing a document's body	covid:93d4534eecee1fe4ccfb36ea1449d53323127a9c#body_text
is schema:about of	named entity 'antimicrobial resistance' named entity 'performed' named entity 'resistant' named entity 'FECAL' named entity 'PRODUCING' named entity 'DISK DIFFUSION' named entity 'ISOLATED' named entity 'DISTRIBUTION' named entity '162' named entity 'DROMEDARY' named entity 'ISOLATED' named entity 'KENYA' named entity 'ANTIMICROBIAL SUSCEPTIBILITY TESTING' named entity 'FECES' named entity 'TOTAL' named entity 'MCR' named entity 'PERFORMED BY' named entity 'PLASMID' named entity 'COLISTIN' named entity 'E. COLI' named entity 'TO DETECT' named entity 'LACTAMASE' named entity 'EXTENDED' named entity 'AFRICAN' named entity 'RESISTANT' named entity 'ANTIMICROBIAL' named entity 'SAMPLES' named entity 'SPECTRUM' named entity 'ESCHERICHIA COLI' named entity 'DROMEDARY' named entity 'SAMPLES' named entity 'FECAL' named entity 'ESCHERICHIA COLI' named entity 'MCR-1' named entity 'CAMELS' named entity 'ANTIMICROBIAL RESISTANCE' named entity 'ISOLATES' named entity 'MEDIATED' named entity 'USING' named entity 'DETERMINE' named entity 'EXTENDED' named entity 'ANTIMICROBIALS' named entity 'PANEL' named entity 'HEALTHY' named entity 'STUDY' named entity 'CAMELS' named entity 'RESISTANCE GENES' named entity 'SPECTRUM' named entity 'LACTAMASES' named entity 'PRESENCE OF' named entity 'ADDITION' covid:arg/93d4534eecee1fe4ccfb36ea1449d53323127a9c named entity 'AST' named entity 'E. coli' named entity 'isolated' named entity 'samples' named entity 'conducted' named entity 'samples' named entity 'feces' named entity 'colistin' named entity 'ampicillin' named entity 'colistin' named entity 'amoxicillin with clavulanic acid' named entity 'Nucleotide sequences' named entity 'ciprofloxacin' named entity 'Tunisia' named entity 'pathogenicity' named entity 'streptomycin' named entity 'Africa' named entity '1, 2' named entity 'sulfamethoxazole/trimethoprim' named entity 'sensu stricto' named entity 'resistance genes' named entity 'multilocus sequence typing' named entity 'fermented' named entity '85%' named entity 'antimicrobials'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software